Encore Vision is developing a topical ophthalmic pharmaceutical treatment for presbyopia, directed at the cause.  The pharmaceutical treatment breaks down excessive biochemical bonds which form with age and restores human lens softness, allowing the lens to change shape and regain focusing / accommodative ability when focusing on near objects.  In-vivo proof of concept in animals has been achieved. Encore Vision is targeting the growing estimated 1.8 Billion presbyope market worldwide of which approximately 100 Million are in the U.S. Multiple patents have been issued and multiple patent applications are pending.

 

PixelOptics | Ocular Optics | Encore Vision | e-Vision | High Performance Optics | Wavefront Systems